Safety of immunotherapy with Alternaria alternata glutaraldehyde–polymerized allergen extract in adults and children
Main Article Content
Keywords
allergic rhinitis, Alternaria alternata, asthma, glutaraldehyde--polymerized extracts, immunotherapy, pediatric allergies, safety
Abstract
Background: Allergies to fungi, such as Alternaria alternata, are significant contributors to respiratory conditions like asthma and rhinitis. Immunotherapy with native A. alternata extracts often results in high rates of adverse reactions. This study evaluates the safety of immunotherapy using glutaraldehyde-polymerized A. alternata extracts in both pediatric and adult populations.
Methods: This observational real-world study involved 738 patients (435 children and 303 adults) monosensitized to A. alternata or polysensitized together to other allergens. Patients received personalized immunotherapy containing polymerized A. alternata extract, either alone or in combination with other polymerized allergens. The concentration of each polymerized allergen in the therapeutic vaccine was 10,000 TU/mL. Side reactions were classified and recorded based on immediate and delayed onset, and their severity was graded according to the EAACI guidelines.
Results: All side reactions were expected and related to the intrinsic properties of allergens. The number of injections administered was 7392, with 4137 to children and 3255 to adults. Thirteen relevant local reactions (0.24% in children, 0.09% in adults) and seven systemic reactions (0.09% overall) were observed. Systemic reactions included mild to moderate symptoms, such as mild bronchospasm and rhinitis. Severe reactions were not reported.
Conclusion: Immunotherapy with glutaraldehyde-polymerized A. alternata, alone or in combination with other polymerized allergens, is safe and well-tolerated in both children and adults. The polymerized extracts allow for higher concentrations and faster administration schedules, providing an effective treatment option for patients with fungal allergies, including those polysensitized to multiple allergens.
References
2 Rick EM, Woolnough K, Pashley CH, Wardlaw AJ. Allergic fungal airway disease. J Investig Allergol Clin Immunol. 2016;26(6):344–54. 10.18176/jiaci.0122
3 Ojeda P, Sastre J, Olaguibel JM, Chivato T, Investigators participating in the National Survey of the Spanish Society of Allergology and Clinical Immunology Alergológica 2015. Alergológica 2015: A national survey on allergic diseases in the adult Spanish population. J Investig Allergol Clin Immunol. 2018;28(3):151–64. 10.18176/jiaci.0264
4 Martínez-Cañavate A, Valenzuela-Soria A, Rojo-Hernández A. Immunotherapy with Alternaria alternata: Present and future. Allergol Immunopathol (Madr). 2007;35(6):259–63. 10.1157/13112993
5 Bogacka E, Nittner-Marszalska M, Fal AM, Kuzniar J, Nikiel E, Malolepszy J. [Allergy to mould allergens as a risk factor for bronchial asthma in patients suffering from allergic rhinitis]. Pol Merkur Lekarski. 2003;14(83):388–92.
6 Arbes SJ, Jr., Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: Results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005;116(2):377–83. 10.1016/j.jaci.2005.05.017
7 Pang C, Bian SN, Liu CH, Guo LL, Cui Y, Lin F, et al. [The characteristics and change of aeroallergens in children from 2015 to 2020 in a hospital of pediatric in Beijing]. Zhonghua Yu Fang Yi Xue Za Zhi. 2021;55(7):840–6.
8 Forkel S, Beutner C, Schröder SS, Bader O, Gupta S, Fuchs T, et al. Sensitization against fungi in patients with airway allergies over 20 years in Germany. Int Arch Allergy Immunol. 2021;182(6):515–23. 10.1159/000512230
9 Vicencio AG, Santiago MT, Tsirilakis K, Stone A, Worgall S, Foley EA, et al. Fungal sensitization in childhood persistent asthma is associated with disease severity. Pediatr Pulmonol 2014; 49(1):8-14. 10.1002/ppul.22779
10 Bozek A, Pyrkosz K. Immunotherapy of mold allergy: A review. Hum Vaccin Immunother. 2017;13(10):2397–401. 10.1080/21645515.2017.1314404
11 Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol. 2011;127(2):502–508 e1-6. 10.1016/j.jaci.2010.11.036
12 Helbling A, Reimers A. Immunotherapy in fungal allergy. Curr Allergy Asthma Rep. 2003;3(5):447–53. 10.1007/s11882-003-0082-x
13 Patterson R, Suszko IM, Zeiss CR, Pruzansky JJ. Development and evaluation of polymerized allergens for immunotherapy. Int Arch Allergy Appl Immunol. 1981;66 Suppl 1:293–6. 10.1159/000232924
14 Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol. 1985;76:397–401. 10.1016/0091-6749(85)90661-X
15 Tudela JI, Cases B, Fernández EA, Pastor C, Casanovas M, Subiza JL, et al. Enzymatic activity in native and polymerised mite allergen extracts. Allergy. 2012;67 (s96):242.
16 Gough L, Campbell E, Bayley D, Van Heeke G, Shakib F. Proteolytic activity of the house dust mite allergen Der p 1 enhances allergenicity in a mouse inhalation model. Clin Exp Allergy. 2003;33(8):1159–63. 10.1046/j.1365-2222.2003.01716.x
17 King C, Brennan S, Thompson PJ, Stewart GA. Dust mite proteolytic allergens induce cytokine release from cultured airway epithelium. J Immunol. 1998;161(7):3645–51. 10.4049/jimmunol.161.7.3645
18 Schulz O, Sewell HF, Shakib F. Proteolytic cleavage of CD25, the alpha subunit of the human T cell interleukin 2 receptor, by Der p 1, a major mite allergen with cysteine protease activity. J Exp Med. 1998;187(2):271–5. 10.1084/jem.187.2.271
19 Cox L, Calderon MA. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: A review of treatment practices in the US and Europe. Curr Med Res Opin. 2010;26(12):2723–33. 10.1185/03007995.2010.528647
20 Migueres M, Dávila I, Frati F, Azpeitia A, Jeanpetit Y, Lhéritier-Barrand M, et al. Types of sensitization to aeroallergens: Definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease. Clin Transl Allergy 2014; 4:16. 10.1186/2045-7022-4-16
21 Álvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen--specific immunotherapy. Allergy. 2006;61 Suppl 82:1–20. 10.1111/j.1398-9995.2006.01219_1.x
22 Álvarez-Cuesta E, Boquete M, Cadahía A, Carrillo T, Fernández-Távora L, Hernández J, et al. Sociedad Española de Alergología e Inmunología Clínica. Normativa sobre Inmunoterapia en Enfermedades Alérgicas. Madrid: SANED; 1990.
23 Martínez-Cañavate A, Eseverri JL, Ródenas R, Tabar AI, Garde J, Torres J, et al. Evaluation of paediatric tolerance to an extract of Alternaria alternata under two treatment regimes. A multicentre study. Allergol Immunopathol (Madr). 2005;33(3):138–41. 10.1157/13075696
24 Tabar AI, Lizaso MT, García BE, Echechipía S, Olaguibel JM, Rodríguez A. Tolerance of immunotherapy with a standardized extract of Alternaria tenuis in patients with rhinitis and bronchial asthma. J Investig Allergol Clin Immunol. 2000;10(6):327–33.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.